- Home
- RM vs BMEA Comparison
RM vs BMEA Comparison
Compare RM & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RM
- BMEA
- Stock Information
- Founded
- RM 1987
- BMEA 2017
- Country
- RM United States
- BMEA United States
- Employees
- RM N/A
- BMEA N/A
- Industry
- RM Finance: Consumer Services
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- RM Finance
- BMEA Health Care
- Exchange
- RM Nasdaq
- BMEA Nasdaq
- Market Cap
- RM 291.2M
- BMEA 275.6M
- IPO Year
- RM 2012
- BMEA 2021
- Fundamental
- Price
- RM $29.69
- BMEA $6.38
- Analyst Decision
- RM Hold
- BMEA Buy
- Analyst Count
- RM 3
- BMEA 13
- Target Price
- RM $31.50
- BMEA $37.25
- AVG Volume (30 Days)
- RM 26.9K
- BMEA 814.9K
- Earning Date
- RM 11-06-2024
- BMEA 10-29-2024
- Dividend Yield
- RM 4.06%
- BMEA N/A
- EPS Growth
- RM N/A
- BMEA N/A
- EPS
- RM 2.41
- BMEA N/A
- Revenue
- RM $556,726,000.00
- BMEA N/A
- Revenue This Year
- RM $13.14
- BMEA N/A
- Revenue Next Year
- RM $5.03
- BMEA N/A
- P/E Ratio
- RM $12.44
- BMEA N/A
- Revenue Growth
- RM 6.00
- BMEA N/A
- 52 Week Low
- RM $20.50
- BMEA $3.61
- 52 Week High
- RM $34.15
- BMEA $22.74
- Technical
- Relative Strength Index (RSI)
- RM 46.30
- BMEA 24.23
- Support Level
- RM $28.94
- BMEA $6.04
- Resistance Level
- RM $30.43
- BMEA $9.34
- Average True Range (ATR)
- RM 1.18
- BMEA 0.54
- MACD
- RM 0.01
- BMEA -0.26
- Stochastic Oscillator
- RM 27.66
- BMEA 10.30
About RM Regional Management Corp.
Regional Management Corp is a diversified consumer finance company that provides installment loan products to customers with limited access to consumer credit from banks, thrifts, credit card companies, and other lenders. It is engaged in consumer finance. The company has the core products which are small and large installment loans. The company also offers optional payment and collateral protection insurance. The company's principal source of revenue is interest and fee income on outstanding loans.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.